Dr. Scott Rocklage, Working to Improve Health Care for Millions

Scott M. Rocklage, Ph.D., is a managing partner at 5AM Ventures. He became a partner at Venture in 2003 and advanced to a managing partner in 2004. Venture 5AM is a company that provides support through venture capital to companies that are currently working to create solutions to healthcare needs through the development of medications and cutting-edge scientific inventions.

Based in Boston, Massachusetts, Dr. Scott Rocklage is an inventor or co-inventor of over 30 U.S. patents. He was written and published more than 100 peer-reviewed publications.

Over the past 30 years, Dr. Rocklage has acquired management experience in healthcare with tactical leadership responsibilities that have led to the approval by the Federal Drug Administration (FDA) of three U.S. New Drug Applications. Those drugs include Omniscan™, a radiocontrast agent that allows doctors to see the brain, spine, chest, stomach, hip, and other areas in MRI scans, Teslascan®, a contrast agent that assists doctors in looking at the liver, and Cubicin®, an antibiotic used to treat serious skin infections in adults and learn more about Scott.

Dr. Rocklage received his B.S. in Chemistry from the University of California in Berkeley and his earned his Ph.D. in chemistry from the Massachusetts Institute of Technology (MIT) where he also conducted research in the laboratory of Richard R. Schrock, who won the Nobel Prize in Chemistry in 2005.

Along with his tenure at 5AM Ventures, Dr. Rocklage currently serves as the chairman and Chief Executive Officer (CEO) of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar and more information click here.

In keeping in line with the busy doctor he is, Dr. Rocklage has served as the chairman of the boards of Novira and Relypsa and currently serves as the chairman of the board at Rennovia, Kinestral and Cidara as well as on the boards of Epirus and Pulmatrix.

Dr. Rocklage also writes about various topics in his blog at https://scottrocklage.wordpress.com.

Leave a Reply

Your email address will not be published. Required fields are marked *